21. Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) in predicting hepatic fibrosis in patients with NAFLD

Abstract

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) is a non invasive tool and authentic diagnostic tool to determine the patients with or without advanced fibrosis. Fibroscan, AST/ALT ratio and NFS can effectively screen to all the patients before subjecting them to liver biopsy thereby reducing the number of overall biopsies required. We aim to compare the severity of liver fibrosis estimated by the non-alcoholic fatty liver disease (NAFLD) fibrosis score and Fibroscan (Vibration controlled Transient Elastography). Methods: Total 130 patients (Mean Age 42.16 ± 11.47) with raised liver enzymes, (29 liver biopsy proven) were included as per the standard inclusion and exclusion criteria. All patients were clinically and biochemically (age, BMI, AST, ALT, Platelets and albumin) evaluated to calculate the NAFLD Fibrosis score and underwent Fibro scan for liver stiffness measurements. The NAFLD fibrosis score (NFS) was used to separate NAFLD patients with and without advanced liver fibrosis (NFS score to classify the probability of fibrosis as <−1.455 for F0-F2 fibrosis, −1.455–0.675 intermediate fibrosis and >0.675 for F3–F4 Fibrosis). Results: Among the 130 patients with NAFLD, there were 74 patients of F1 Fibroscan score, followed by 28 patients of F2, and 14 patients each with F3 and F4 Fibroscan score. NAFLD fibrosis score was intermediate for 63.5% of patients among F1 Fibroscan score patients (Table 1). NAFLD fibrosis score F0-F2, sensitivity and specificity was 100% and 7.8% and for intermediate NAFLD fibrosis score, sensitivity and specificity was 71.4% and 62.9%.Table 1LSM GroupTotalF1F2F3F4NFS GroupF0-F2Count35109% within LSM Group4.1%17.9%7.1%0.0%6.9%IntermediateCount4798468% within LSM Group63.5%32.1%57.1%28.6%52.3%F3-F4Count241451053% within LSM Group32.4%50.0%35.7%71.4%40.8%TotalCount74281414130 Open table in a new tab Conclusions: NFS correlate well with fibro scan and liver histology in assessing the hepatic fibrosis and can we be used as a non invasive fibrosis marker. The authors have none to declare.